Yale Startup Kolltan Pharmaceuticals Nets $35M in VC Financing to Develop Cancer Rx

Those close to the deal attribute the unusually large investment to the involvement of Yale researcher and tyrosine kinase pioneer Joseph Schlessinger and other entrepreneurs involved with 1990s biotech startup Sugen.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.